$PPYA
Papaya Growth Opportunity Corp I Stock $ppya

$ppya Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000141057824000372 Filed on April 01, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$481.4K	$2.107M
YoY Change	-27.65%	-1.02%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$481.4K	$2.107M
YoY Change	-27.65%	-1.02%
Operating Profit
YoY Change
Interest Expense	$307.9K	$6.088M
YoY Change	-87.76%	40.99%
% of Operating Profit
Other Income/Expense, Net		$6.088M
YoY Change		40.99%
Pretax Income	-$173.4K	$3.981M
YoY Change	-109.37%	81.84%
Income Tax	-$2.640K	$1.553M
% Of Pretax Income		39.01%
Net Earnings	-$170.8K	$2.428M
YoY Change	-114.1%	56.6%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.02	$0.11
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.010K	$2.010K
YoY Change	-99.37%	-99.37%
Cash & Equivalents	$2.013K
Short-Term Investments
Other Short-Term Assets	$84.68K	$84.68K
YoY Change	-67.13%	-67.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$139.7K	$139.7K
YoY Change	-75.81%	-75.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$24.98M	$24.98M
YoY Change	-91.61%	-91.61%
Other Assets	$542.8K	$542.8K
YoY Change
Total Long-Term Assets	$25.52M	$25.52M
YoY Change	-91.42%	-91.42%
TOTAL ASSETS
Total Short-Term Assets	$139.7K	$139.7K
Total Long-Term Assets	$25.52M	$25.52M
Total Assets	$25.66M	$25.66M
YoY Change	-91.39%	-91.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$481.0K	$481.0K
YoY Change	115.06%	115.06%
Accrued Expenses	$2.770M	$2.770M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$2.624M	$2.624M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.21M	$21.21M
YoY Change	36.07%	36.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.21M	$21.21M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$21.21M	$21.21M
YoY Change	31.39%	31.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.53M
YoY Change	82.5%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.444M	$4.444M
YoY Change
Total Liabilities & Shareholders Equity	$25.66M	$25.66M
YoY Change	-91.39%	-91.39%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$170.8K	$2.428M
YoY Change	-114.1%	56.6%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$330.0K	-$4.356M
YoY Change	-30.52%	111.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$40.00K	$278.6M
YoY Change		-195.01%
Cash From Investing Activities	$40.00K	$278.6M
YoY Change		-195.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$277.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	289.1K	-274.6M
YoY Change		-192.89%
NET CHANGE
Cash From Operating Activities	-330.0K	-4.356M
Cash From Investing Activities	40.00K	278.6M
Cash From Financing Activities	289.1K	-274.6M
Net Change In Cash	-900.0	-318.1K
YoY Change	-99.81%	-206.7%
FREE CASH FLOW
Cash From Operating Activities	-$330.0K	-$4.356M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2023Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001894057
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2022Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2023	us-gaap	Operating Cost And Expense Related Party Type Extensible Enumeration OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2022	us-gaap	Operating Cost And Expense Related Party Type Extensible Enumeration OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41223
CY2023	dei	Entity Registrant Name EntityRegistrantName	PAPAYA GROWTH OPPORTUNITY CORP. I
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-3071107
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2201 Broadway, #705
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Oakland,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94612
CY2023	dei	City Area Code CityAreaCode	510
CY2023	dei	Local Phone Number LocalPhoneNumber	214-3750
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	2468
CY2023	dei	Auditor Name AuditorName	Citrin Cooperman & Company, LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	103800000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2013
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	320067
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43677
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216608
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	41000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	41000
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	53054
CY2023Q4	us-gaap	Assets Current AssetsCurrent	139744
CY2022Q4	us-gaap	Assets Current AssetsCurrent	577675
CY2023Q4	ppya	Deferred Tax Asset Non Current DeferredTaxAssetNonCurrent	542806
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	24976375
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	297568272
CY2023Q4	us-gaap	Assets Assets	25658925
CY2022Q4	us-gaap	Assets Assets	298145947
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	480958
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	223640
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	174000
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	14500
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2624070
CY2023Q4	ppya	State Franchise Tax Payable Current StateFranchiseTaxPayableCurrent	40200
CY2022Q4	ppya	State Franchise Tax Payable Current StateFranchiseTaxPayableCurrent	200800
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2770478
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	27000
CY2023Q4	ppya	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	15125000
CY2022Q4	ppya	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	15125000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21214706
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15590940
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	555020
CY2023Q4	us-gaap	Liabilities Liabilities	21214706
CY2022Q4	us-gaap	Liabilities Liabilities	16145960
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	24976375
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	293250000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20533046
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11250903
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-20532156
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11250013
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25658925
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298145947
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1907007
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1928794
CY2023	ppya	Franchise Tax Expense FranchiseTaxExpense	200000
CY2022	ppya	Franchise Tax Expense FranchiseTaxExpense	200000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	2107007
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	2128794
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	5608405
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	497081
CY2023	ppya	Realized Gain Loss On Investments Held In Trust Account RealizedGainLossOnInvestmentsHeldInTrustAccount	479857
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3821190
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6088262
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4318271
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3981255
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2189477
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1553174
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	639020
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2428081
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1550457
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11250013
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	8939746
CY2023	ppya	Adjustments To Additional Paid In Capital Excise Tax Payable AdjustmentsToAdditionalPaidInCapitalExciseTaxPayable	2770478
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2428081
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-20532156
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7972
CY2022	ppya	Sale Of Private Placement Units Including Over Allotment SaleOfPrivatePlacementUnitsIncludingOverAllotment	13655000
CY2022	ppya	Proceeds From Initial Public Offering Costs Allocated To Public Warrants Shares Amount ProceedsFromInitialPublicOfferingCostsAllocatedToPublicWarrantsSharesAmount	6272244
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	32719742
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1550457
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11250013
CY2023	us-gaap	Profit Loss ProfitLoss	2428081
CY2022	us-gaap	Profit Loss ProfitLoss	1550457
CY2023	ppya	Interest On Investment Held In Trust Account InterestOnInvestmentHeldInTrustAccount	5608405
CY2022	ppya	Interest On Investment Held In Trust Account InterestOnInvestmentHeldInTrustAccount	497081
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3821190
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	479857
CY2023	ppya	Deferred Tax Expense Operating Activities DeferredTaxExpenseOperatingActivities	1097826
CY2022	ppya	Deferred Tax Expense Operating Activities DeferredTaxExpenseOperatingActivities	-555020
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-172931
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	216608
CY2023	us-gaap	Increase Decrease In Due To Affiliates Current IncreaseDecreaseInDueToAffiliatesCurrent	159500
CY2022	us-gaap	Increase Decrease In Due To Affiliates Current IncreaseDecreaseInDueToAffiliatesCurrent	14500
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	257318
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	171578
CY2022	ppya	Increase Decrease Advance Tax Payables IncreaseDecreaseAdvanceTaxPayables	41000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-27000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	27000
CY2023	ppya	Increase Decrease Franchise Tax Payables IncreaseDecreaseFranchiseTaxPayables	-160600
CY2022	ppya	Increase Decrease Franchise Tax Payables IncreaseDecreaseFranchiseTaxPayables	200000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4355858
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2057324
CY2023	ppya	Proceeds From Withdrawal Of Cash From Trust Account For Tax Payments ProceedsFromWithdrawalOfCashFromTrustAccountForTaxPayments	3136650
CY2023	ppya	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	1722916
CY2022	ppya	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	293250000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	277213371
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	278627105
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-293250000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	277213371
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-145000
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2624070
CY2022	ppya	Net Proceeds From Initial Public Offering NetProceedsFromInitialPublicOffering	282500000
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	13655000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	404600
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-274589301
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	295605400
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-318054
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	298076
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	320067
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21991
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2013
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	320067
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2692000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	57000
CY2022	ppya	Deferred Underwriting Commissions Payable DeferredUnderwritingCommissionsPayable	15125000
CY2022	ppya	Initial Classification Of Common Stock Subject To Possible Redemption InitialClassificationOfCommonStockSubjectToPossibleRedemption	293250000
CY2023	ppya	Adjustments To Additional Paid In Capital Excise Tax Payable AdjustmentsToAdditionalPaidInCapitalExciseTaxPayable	2770478
CY2023	ppya	Accretion For Class Common Stock To Redemption Value AccretionForClassCommonStockToRedemptionValue	8939746
CY2022	ppya	Accretion For Class Common Stock To Redemption Value AccretionForClassCommonStockToRedemptionValue	32719742
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1 — Description of Organization, Business Operations and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Papaya Growth Opportunity Corp. I (the “Company”) was incorporated in Delaware on October 8, 2021. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (the “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had not commenced any operations. All activity from October 8, 2021 (inception) through December 31, 2023, relates to the Company’s formation and Initial Public Offering (“IPO”), which is described below and, since the IPO, the search for a prospective Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income earned on investments from the proceeds derived from the IPO held in the Trust Account (defined below).The registration statement for the Company’s IPO was declared effective on January 13, 2022. On January 19, 2022, the Company consummated the IPO of 25,000,000 units (“Units”), including shares of Class A common stock in the Units offered (the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $250,000,000, which is discussed in Note 3. The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the IPO, the Company consummated the sale of 1,290,500 private placement units (“Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to the Company’s sponsor, Papaya Growth Opportunity I Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald & Co. (“Cantor”), and J.V.B. Financial Group, LLC on behalf of its Cohen & Company Capital Markets division (“CCM”), generating gross proceeds of $12,905,000 which is described in Note 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the IPO and the sale of the Private Placement Units, the Company consummated the sale of 3,750,000 additional Units upon receiving notice of the underwriter’s election to fully exercise its overallotment option (“Overallotment Units”), generating additional gross proceeds of $37,500,000. Simultaneously with the exercise of the overallotment, the Company consummated the private placement of an additional 75,000 Private Placement Units to the Sponsor, generating gross proceeds of $750,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs for the IPO and sale of the Private Placement Units and Overallotment Units amounted to $20,697,498, consisting of $5,000,000 of upfront underwriting fees, $15,125,000 of deferred underwriting fees payable (which are held in the Trust Account), and $572,498 of other offering costs. As described in Note 6, the $15,125,000 of deferred underwriting fees payable is contingent upon the consummation of a Business Combination by up to January 19, 2025, 36 months from the closing of the IPO, subject to the terms of the underwriting agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the IPO and the sale of the Private Placement Units and Overallotment Units, $293,250,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the IPO, Overallotment Units, and the Private Placement Units was placed in a trust account (“Trust Account”). The amounts placed in the Trust Account are invested in (i) interest - bearing bank demand deposit accounts, (ii) uninvested, (iii) U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or (iv) money market funds selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3), (d)(4) and (d)(5) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Units and Overallotment Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.20 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation (the “Certificate of Incorporation”). In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC 480”) Subtopic 10-S99, redemption provisions not solely within the control of a company require Class A common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares were issued with other freestanding instruments (i.e., Public Warrants as defined in Note 3), the initial carrying value of the Public Shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20 “Debt with Conversion and other Options”. The Public Shares are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. The Public Shares are redeemable and are classified as such on the balance sheet until such date that a redemption event takes place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Redemptions of the Company’s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s Business Combination. If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Placement Shares (as defined in Note 4), Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares sold in the IPO, without the prior consent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s Sponsor, officers and directors (the “Initial Stockholders”) have agreed not to propose an amendment to the Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares of Class A common stock in conjunction with any such amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 12, 2023, the Company’s stockholders approved an amendment (the “Extension Amendment”) to the Certificate of Incorporation to extend the date by which the Company must consummate an initial business combination up to six (6) times for an additional one (1) month each time, from April 19, 2023 to October 19, 2023 (which is 21 months from the closing of the IPO).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 30, 2023, the Company’s stockholders approved an amendment to the Certificate of Incorporation to extend the date by which the Company must consummate an initial business combination up to four (4) times for an additional (1) month each time from October 19, 2023 to February 19, 2024 by depositing into the Company’s trust account for each one-month extension the lesser of (a) $30,000 and (b) $0.03 for each then outstanding share after giving effect to any redemptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 7, 2023, Papaya Growth Opportunity Corp. I, a Delaware corporation (the “Company”), received a letter (the “Letter”) from the staff at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 16, 2024, the Company’s stockholders approved an amendment to the Certificate of Incorporation to extend the date by which the Company must consummate an initial business combination up to eleven (11) times for an additional (1) month each time from February 19, 2024 to January 19, 2025 by depositing into the Company’s trust account for each one-month extension the lesser of (a) $30,000 and (b) $0.02 for each then outstanding share after giving effect to any redemptions. If a Business Combination is not consummated by January 19, 2025, which is 36 months from the closing of the IPO, in compliance with the requirements set forth in the Certificate of Incorporation for such an extension (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_yCN9RJVquEaHuZkhfyYwZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay (a) its income and franchise taxes and (b) up to $100,000 of dissolution expenses, if any, divided by the number of then outstanding Public Shares, whose redemption will completely extinguish the Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares (as defined in Note 5) and the Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders should acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only the $10.20 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity, Going Concern, and Management’s Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the IPO, the Company lacked the liquidity it needed to sustain operations for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. The Company has since completed its IPO at which time capital in excess of the funds deposited in the Trust Account and/or used to fund offering expenses was released to the Company for general working capital purposes. Accordingly, management has since re-evaluated the Company’s liquidity and financial condition and determined that the Company will need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs and there is no guarantee that the Company will receive such funds. As of December 31, 2023, the Company does not have sufficient working capital and will need to borrow additional funds from its Sponsor in order to fund its operations through one year from the date of this filing. As of December 31, 2023, the Company had cash of $2,013 and a working capital deficit of $609,268. As of the date of the financial statements, $224,000 has been drawn from the $1.2 million promissory note provided from the Sponsor on February 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution described in Note 1, should the Company be unable to complete a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern. The Company has until January 19, 2025, 36 months from the closing of the IPO, to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination during the specified period. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. As is customary for a special purpose acquisition company, if the Company is not able to consummate a Business Combination by January 19, 2025, it will cease all operations and redeem the Public Shares. Management plans to continue its efforts to consummate a Business Combination prior to January 19, 2025.</p>
CY2023	ppya	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
CY2022Q1	ppya	Sale Of Stock Offering Costs SaleOfStockOfferingCosts	20697498
CY2022Q1	ppya	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	5000000
CY2022Q1	ppya	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	15125000
CY2022Q1	ppya	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	572498
CY2022Q1	ppya	Aggregate Deferred Underwriting Fee Payable AggregateDeferredUnderwritingFeePayable	15125000
CY2023	ppya	Months To Complete Business Combination MonthsToCompleteBusinessCombination	P36M
CY2022Q1	ppya	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	293250000
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.20
CY2023	ppya	Investments Maximum Maturity Term InvestmentsMaximumMaturityTerm	P185D
CY2023	ppya	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	80
CY2023	ppya	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	50
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.20
CY2023	ppya	Threshold Percentage Of Public Shares Subject To Redemption Without Company Prior Written Consent ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanyPriorWrittenConsent	0.15
CY2023	ppya	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1
CY2023Q2	ppya	Months To Complete Business Combination MonthsToCompleteBusinessCombination	P21M
CY2023Q3	ppya	Business Combination Conditions Deposits In Trust Account Maximum BusinessCombinationConditionsDepositsInTrustAccountMaximum	30000
CY2023Q3	ppya	Business Combination Conditions Maximum Deposits In Trust Account Per Share Of Outstanding Share Net Of Redemptions BusinessCombinationConditionsMaximumDepositsInTrustAccountPerShareOfOutstandingShareNetOfRedemptions	0.03
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.20
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2013
CY2023Q4	ppya	Working Capital Deficit WorkingCapitalDeficit	609268
CY2023	ppya	Months To Complete Business Combination MonthsToCompleteBusinessCombination	P36M
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	24976375
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	297568272
CY2023Q4	ppya	Assets Held In Trust Account In Cash Number Of Financial Institutions AssetsHeldInTrustAccountInCashNumberOfFinancialInstitutions	1
CY2023Q3	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.6897
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of December 31, 2023, and December 31, 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2794
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2984
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1800000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	57000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	851000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1097826
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	555020
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1553174
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	639020
CY2023Q4	ppya	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	542806
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	542806
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	555020
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	542806
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	555020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1910
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0884
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0884
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2794
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2984
CY2023	ppya	Number Of Shares Issued Per Unit NumberOfSharesIssuedPerUnit	2
CY2023	ppya	Number Of Shares Issued Per Unit NumberOfSharesIssuedPerUnit	2
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2021Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.0102482
CY2023	ppya	Underwriting Cash Discount Per Unit UnderwritingCashDiscountPerUnit	0.50
CY2023	ppya	Aggregate Underwriter Cash Discount AggregateUnderwriterCashDiscount	12500000
CY2023Q4	ppya	Deferred Fee Per Unit DeferredFeePerUnit	0.70
CY2023	ppya	Aggregate Deferred Underwriting Fee Payable AggregateDeferredUnderwritingFeePayable	15125000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2013
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	320067
CY2023Q4	ppya	Maturity Term Of Funds Held In Government Treasury Obligations MaturityTermOfFundsHeldInGovernmentTreasuryObligations	P90D

Files In Submission

Name	View Source	Status
0001410578-24-000372-index-headers.html	Edgar Link	pending
0001410578-24-000372-index.html	Edgar Link	pending
0001410578-24-000372.txt	Edgar Link	pending
0001410578-24-000372-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ppya-20231231.xsd	Edgar Link	pending
ppya-20231231x10k.htm	Edgar Link	pending
ppya-20231231xex21d1.htm	Edgar Link	pending
ppya-20231231xex31d1.htm	Edgar Link	pending
ppya-20231231xex31d2.htm	Edgar Link	pending
ppya-20231231xex32d1.htm	Edgar Link	pending
ppya-20231231xex32d2.htm	Edgar Link	pending
ppya-20231231xex97d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
ppya-20231231_cal.xml	Edgar Link	unprocessable
ppya-20231231_def.xml	Edgar Link	unprocessable
ppya-20231231_lab.xml	Edgar Link	unprocessable
ppya-20231231_pre.xml	Edgar Link	unprocessable
ppya-20231231x10k_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPYA
Papaya Growth Opportunity Corp I Stock $ppya

2023 Q4 Form 10-K Financial Statement

#000141057824000372 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPYA Papaya Growth Opportunity Corp I Stock $ppya

2023 Q4 Form 10-K Financial Statement

#000141057824000372 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPYA
Papaya Growth Opportunity Corp I Stock $ppya